LAS VEGAS, Sept. 30, 2013 /PRNewswire/ - Vansen Pharma Inc. [OTCBB: VNSN] is pleased to announce that effective today the company's common shares
will begin trading under its new ticker symbol, "VNSN".
The Financial Industry Regulatory Authority (FINRA) previously approved
the company's request to change its name from Okana Ventures Inc.
(OTCBB: OKNVD) to Vansen Pharma Inc., better reflecting the nature of
its core business operations.
About Vansen Pharma Inc.
Vansen Pharma Inc. is a specialty pharmaceutical company focused on
broad therapeutic areas that are anticipated to grow and present an
opportunity for major expansion. Vansen will expand its commercial
presence by adding complimentary products through in-licensing,
co-promotion and acquisitions, resulting in a comprehensive product
portfolio. With its US based sales force, Vansen can better serve the
increasing healthcare needs of patients and enhance growth.
Certain statements contained in this press release may constitute
"forward-looking statements" within the meaning of Section 21E (i) (1)
of the United States Securities Exchange Act of 1934. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Vansen's actual results
to be materially different from any future results expressed or implied
by these statements. Such factors include the following: general
economic and business conditions, changes in demand for Vansen's
products, changes in competition, the ability of Vansen to integrate
acquisitions or complete future acquisitions, interest rate
fluctuations, currency exchange rate fluctuations, dependence upon and
availability of qualified personnel and changes in government
regulation. In light of these and other uncertainties, the
forward-looking statements included in this press release should not be
regarded as a representation by Vansen that Vansen's plans and
objectives will be achieved. These forward-looking statements speak
only as of the date of this press release, and we undertake no
obligation to update or revise the statements.
SOURCE Vansen Pharma Inc.